CoChat

Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property

Open access

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

PARP1 trapping at DNA lesion by pharmacological inhibitors has been exploited in several cancers exhibiting defects in DNA repair mechanisms. PARP1 hyperactivation is involved in therapeutic resistance in multiple cancers. The role of PARP1 in cervical cancer (CC) resistance and implication of PARP inhibitor is yet to be elucidated. Our data demonstrates significantly higher expression of PARP1 in primary cervical tumors and CC cell lines SiHa and ME180. Upon cisplatin treatment CC cells display significant overexpression of PARP1 and its hyperactivation. PARP inhibitor olaparib shows significant anti-proliferative effect on CC cells and drive loss of clonogenic survival and enhanced cell death in combination with cisplatin. PARP inhibited cells show delay in resolution of γH2A.X foci and prolonged late S and G2-M phase arrest resulting in apoptosis. Further, PARP inhibition disrupts the localization of base excision repair (BER) effector XRCC1 and non-homologous end joining (NHEJ) proteins Ku80 and XRCC4. Due to disrupted relocation of repair factors, cisplatin induced stalled replication forks collapse and convert into double strand breaks (DSBs). Interestingly, PARP inhibition also shows anti-migratory and anti-invasive properties in CC cells, increases anchorage independent cell death and induces anoikis. Collectively, our data demonstrates therapeutic potential of PARP inhibitor in cervical cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-13232-3

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Expression of PARP1 in primary tissue samples and CC cell lines; (A) Bar graph displaying quantitative mRNA expression of PARP1 in normal samples (n = 15) and tumor samples (35) along with two cervical cancer cell lines SiHa and ME180. (normal vs. tumor **p = 0.0035, normal vs. cell lines *p = 0.0359, tumor vs. cell lines p = 0.3993. (B) Western blots displaying expression of PARP1 protein in normal and tumor samples as well as in CC cell lines.The full size blots corresponding to the cropped blot images are given in Supplementary Figure S12. (C) Bar graph showing relative quantification of protein expression normalized to GAPDH. (D) Representative immunofluorescence image showing nuclear localization of PARP1 as foci in SiHa and ME180 cell lines. (E) Representative image showing nuclear PARP1 expression in tumor samples from CC patient. Normal samples do not show any nuclear staining. However, IIIB samples have greater staining intensity than IIB.
Figure 1 Expression of PARP1 in primary tissue samples and CC cell lines; (A) Bar graph displaying quantitative mRNA expression of PARP1 in normal samples (n = 15) and tumor samples (35) along with two cervical cancer cell lines SiHa and ME180. (normal vs. tumor **p = 0.0035, normal vs. cell lines *p = 0.0359, tumor vs. cell lines p = 0.3993. (B) Western blots displaying expression of PARP1 protein in normal and tumor samples as well as in CC cell lines.The full size blots corresponding to the cropped blot images are given in Supplementary Figure S12. (C) Bar graph showing relative quantification of protein expression normalized to GAPDH. (D) Representative immunofluorescence image showing nuclear localization of PARP1 as foci in SiHa and ME180 cell lines. (E) Representative image showing nuclear PARP1 expression in tumor samples from CC patient. Normal samples do not show any nuclear staining. However, IIIB samples have greater staining intensity than IIB.CC BY · PubMed Central
Figure 2 Cisplatin induces PARP1 over expression and hyperactivation in CC cell lines. (A) Graph showing relative PARP1 mRNA expression in SiHa and ME180 CC cell lines after 24 hr cisplatin (10μM) treatment. (SiHa control vs. cisplatin *p = 0.0205, ME180 control vs. cisplatin *p = 0.0351). (B) Representative western blot showing expression of PARP1 and PAR polymers in SiHa and ME180 cell lines treated with 5 µM and 10 µM cisplatin for 48 hrs. Bar graph displaying normalized band density of PARP1 and PAR normalized to GAPDH. Error bar display the S.D. from the mean of 3 independent experiments. *p = 0.01,**p = 0.007. The full size blots corresponding to the cropped blot images are given in Supplementary Figure S12. (C) Western blot showing PARP1 and PAR expression in SiHa and ME180 cell lines treated with 5µM and 10µM for indicated time duration. Bar graph displaying normalized band density of PARP1 and PAR normalized to GAPDH band intensity of respective blot image. The full size blots corresponding to the cropped blot images are given in Supplementary Figure S12. (D) Transfection with specific PARP1 siRNA shows depletion in basal PARP1 protein level as well as cisplatin induced PARP1 overexpression. Bar graph displaying relative protein expression normalized to GAPDH. The full size blots corresponding to the cropped blot images are given in Supplementary Figure S12. (E) Representative immunofluorescence image showing nuclear localization of PARP1 in SiHa and ME180 cell lines. 24 hrs cisplatin treated cell shows enhanced number of PARP1 foci in both cell lines. Bar graph displaying quantitative distribution of PARP1 foci in respective treatment groups.
Figure 2 Cisplatin induces PARP1 over expression and hyperactivation in CC cell lines. (A) Graph showing relative PARP1 mRNA expression in SiHa and ME180 CC cell lines after 24 hr cisplatin (10μM) treatment. (SiHa control vs. cisplatin *p = 0.0205, ME180 control vs. cisplatin *p = 0.0351). (B) Representative western blot showing expression of PARP1 and PAR polymers in SiHa and ME180 cell lines treated with 5 µM and 10 µM cisplatin for 48 hrs. Bar graph displaying normalized band density of PARP1 and PAR normalized to GAPDH. Error bar display the S.D. from the mean of 3 independent experiments. *p = 0.01,**p = 0.007. The full size blots corresponding to the cropped blot images are given in Supplementary Figure S12. (C) Western blot showing PARP1 and PAR expression in SiHa and ME180 cell lines treated with 5µM and 10µM for indicated time duration. Bar graph displaying normalized band density of PARP1 and PAR normalized to GAPDH band intensity of respective blot image. The full size blots corresponding to the cropped blot images are given in Supplementary Figure S12. (D) Transfection with specific PARP1 siRNA shows depletion in basal PARP1 protein level as well as cisplatin induced PARP1 overexpression. Bar graph displaying relative protein expression normalized to GAPDH. The full size blots corresponding to the cropped blot images are given in Supplementary Figure S12. (E) Representative immunofluorescence image showing nuclear localization of PARP1 in SiHa and ME180 cell lines. 24 hrs cisplatin treated cell shows enhanced number of PARP1 foci in both cell lines. Bar graph displaying quantitative distribution of PARP1 foci in respective treatment groups.CC BY · PubMed Central
Figure 3 Effect of olaparib on cisplatin mediated PARP1 hyperactivation. (A) SiHa and ME180 cells were treated with cisplatin and/or olaparib for 48 hrs and expression of PARP1 and PAR was determined by western blot. Olaparib exerts strong anti-PARP activity in cisplatin treated CC cells.The full size blots corresponding to the cropped blot images are given in Supplementary Figure S12. (B) Bar graph displaying relative PARylation normalized to GAPDH in both cell lines. Error bars display the S.D. from the mean of 3 independent experiments. **p = 0.0095. (C) Representative immunofluorescence image showing nuclear co-localization of PAR polymers with γH2A.X foci. 24 hr cisplatin treated cells show higher PAR polymers signals compare to untreated and signal was completely suppressed after olaparib treatment or PARP1 siRNA transfection. (D) Bar graph displaying quantification of γH2A.X+ PAR− or γH2A.X+ PAR+ cell distribution in cisplatin and/or olaparib treated along with PARP1 silenced cells treated with cisplatin.
Figure 3 Effect of olaparib on cisplatin mediated PARP1 hyperactivation. (A) SiHa and ME180 cells were treated with cisplatin and/or olaparib for 48 hrs and expression of PARP1 and PAR was determined by western blot. Olaparib exerts strong anti-PARP activity in cisplatin treated CC cells.The full size blots corresponding to the cropped blot images are given in Supplementary Figure S12. (B) Bar graph displaying relative PARylation normalized to GAPDH in both cell lines. Error bars display the S.D. from the mean of 3 independent experiments. **p = 0.0095. (C) Representative immunofluorescence image showing nuclear co-localization of PAR polymers with γH2A.X foci. 24 hr cisplatin treated cells show higher PAR polymers signals compare to untreated and signal was completely suppressed after olaparib treatment or PARP1 siRNA transfection. (D) Bar graph displaying quantification of γH2A.X+ PAR− or γH2A.X+ PAR+ cell distribution in cisplatin and/or olaparib treated along with PARP1 silenced cells treated with cisplatin.CC BY · PubMed Central
Figure 4 Olaparib increases cisplatin induced lethality in CC cells. (A) Cell proliferation assay was carried out to determine the anti-proliferative potential of cisplatin and olaparib in indicated concentration for 72 hrs drug incubation and proliferation was assessed by MTT assay. Data indicate that both the drugs were able to inhibit cellular proliferation of CC cell lines SiHa and ME180. (B) Both the cell lines were treated with cisplatin and/or olaparib for indicated duration or indicated drug concentration of each drugs, cell proliferation was determined by MTT assay. Data indicates that olaparib significantly augment the cisplatin induced cell cytotoxicity in CC cell lines. (C) Olaparib treatment significantly enhanced cisplatin induced loss of clonogenic survival of CC cells.
Figure 4 Olaparib increases cisplatin induced lethality in CC cells. (A) Cell proliferation assay was carried out to determine the anti-proliferative potential of cisplatin and olaparib in indicated concentration for 72 hrs drug incubation and proliferation was assessed by MTT assay. Data indicate that both the drugs were able to inhibit cellular proliferation of CC cell lines SiHa and ME180. (B) Both the cell lines were treated with cisplatin and/or olaparib for indicated duration or indicated drug concentration of each drugs, cell proliferation was determined by MTT assay. Data indicates that olaparib significantly augment the cisplatin induced cell cytotoxicity in CC cell lines. (C) Olaparib treatment significantly enhanced cisplatin induced loss of clonogenic survival of CC cells.CC BY · PubMed Central
Figure 5 PARP1 inhibition stalls replication fork and induces DSBs. (A) Representative immunofluorescence of RPA and γH2A.X foci in cisplatin and/or olaparib treated cell CC cell lines along with PARP1 silenced cell treated with cisplatin. (B) Quantification of percentage of cells with >20 RPA foci/cell in indicated treatment groups (cisplatin vs. cisplatin + olaparib and PARP1 siRNA vs. PARP1 siRNA + cisplatin *p < 0.05). (C) Representative immunofluorescence of 53BP1 foci and γH2A.X foci in indicated treatment or siRNA transfection in CC cells. Cisplatin and olaparib both induce 53BP1 foci in CC cell line but combination of both drug or cisplatin treatment in PARP1 depleted cells produces higher number of 53BP1 foci and display more number of γH2A.X foci which co-localizes with each other. (D) Quantification plot showing percentage of cells showing >20 53BP1 foci in mentioned treatment groups and γH2A.X+53BP1+cells in respective mentioned groups.
Figure 5 PARP1 inhibition stalls replication fork and induces DSBs. (A) Representative immunofluorescence of RPA and γH2A.X foci in cisplatin and/or olaparib treated cell CC cell lines along with PARP1 silenced cell treated with cisplatin. (B) Quantification of percentage of cells with >20 RPA foci/cell in indicated treatment groups (cisplatin vs. cisplatin + olaparib and PARP1 siRNA vs. PARP1 siRNA + cisplatin *p < 0.05). (C) Representative immunofluorescence of 53BP1 foci and γH2A.X foci in indicated treatment or siRNA transfection in CC cells. Cisplatin and olaparib both induce 53BP1 foci in CC cell line but combination of both drug or cisplatin treatment in PARP1 depleted cells produces higher number of 53BP1 foci and display more number of γH2A.X foci which co-localizes with each other. (D) Quantification plot showing percentage of cells showing >20 53BP1 foci in mentioned treatment groups and γH2A.X+53BP1+cells in respective mentioned groups.CC BY · PubMed Central
Figure 6 PARP1 inhibition sensitizes CC cells and leads to rapid induction of DNA damage and cell death. (A) Bar graph showing the percentage of γH2A.X foci positive cells (cell with >20 positive foci/cell as compared to isotype) in indicated groups at particular treatment duration. At least 200 cells were counted in blind fashion in independent duplicate experiment. Error bar show SD from the mean of two independent counts. *p = 0.05, **p < 0.01, ***p < 0.001 (upper panel); Bar graph showing the percentage of γH2A.X foci positive cells in PARP1 silenced and control counterpart cells treated with 5 µM cisplatin for indicated time points. At least 200 cells were counted in blind fashion in independent duplicate experiment. Error bar display SD from the mean of two independent counts. *p = 0.05, **p < 0.01, ***p < 0.001 (lower panel). (B) Cell proliferation assay displaying effect of cisplatin on PARP1 silenced CC cells. (C) PARP1 silenced cells showing increased loss of clonogenic survival after cisplatin treatment in CC cells.
Figure 6 PARP1 inhibition sensitizes CC cells and leads to rapid induction of DNA damage and cell death. (A) Bar graph showing the percentage of γH2A.X foci positive cells (cell with >20 positive foci/cell as compared to isotype) in indicated groups at particular treatment duration. At least 200 cells were counted in blind fashion in independent duplicate experiment. Error bar show SD from the mean of two independent counts. *p = 0.05, **p < 0.01, ***p < 0.001 (upper panel); Bar graph showing the percentage of γH2A.X foci positive cells in PARP1 silenced and control counterpart cells treated with 5 µM cisplatin for indicated time points. At least 200 cells were counted in blind fashion in independent duplicate experiment. Error bar display SD from the mean of two independent counts. *p = 0.05, **p < 0.01, ***p < 0.001 (lower panel). (B) Cell proliferation assay displaying effect of cisplatin on PARP1 silenced CC cells. (C) PARP1 silenced cells showing increased loss of clonogenic survival after cisplatin treatment in CC cells.CC BY · PubMed Central
Figure 7 PARP1 inhibition delayed DNA repair and leads to prolonged cell cycle arrest at G2/M. (A) Both the cell lines SiHa and ME180 were treated with 10 µM cisplatin and/or olaparib for 24 hrs. After 24 hrs drug was removed (DR0) and fresh drug free media was added. Cells were cultured further and γH2A.X foci were observed very 24 hr till 10 days post drug removal (DR0 to DR10). Cells with >20 γH2A.X foci to 0 foci were counted in blind fashion and at least 200 cells per group in several different 60× objective fields were acquired. Quantitative plot displaying distribution of γH2A.X foci in three treatment groups in both the cell lines. [Time point DR3, frequency of cells with more than 20 foci per cell in SiHa; cisplatin vs. cisplatin + olaparib *p = 0.0467, at DR4; cisplatin vs. cisplatin + olaparib *p = 0.0268, at DR5; cisplatin vs. cisplatin + olaparib **p = 0.0060 and frequency of cells with more than 20 foci per cell in ME180 at DR3; cisplatin vs. cisplatin + olaparib *p = 0.0390, at DR4; cisplatin vs. cisplatin + olaparib *p = 0.041, at DR5; cisplatin vs. cisplatin + olaparib **p = 0.0024]. (B) Both the cell lines SiHa and ME180 were treated as indicated and cell were stained with FITC tagged anti γH2A.X & co-stained with PI and analysis was done using FACS for DNA damage in each cell cycle phases. Graph showing the percentage of cells with γH2A.X foci in SiHa and ME180 cell lines. PARP1 inhibition in cisplatin treated cells shows significant accumulation of DNA damage in late S and G2/M phase compared to G1. (C) Graph showing frequency of γH2A.X foci resolution in PARP1 silenced and control counterpart after cisplatin treatment. PARP1 silenced cells displayed significant delay in γH2A.X foci resolution after drug removal. (D) Similarly, PARP inhibition along with cisplatin treatment for 48 hrs shows significant & prolonged G2/M and late S phase arrest in both the cell lines after drug removal as in previous experiments.
Figure 7 PARP1 inhibition delayed DNA repair and leads to prolonged cell cycle arrest at G2/M. (A) Both the cell lines SiHa and ME180 were treated with 10 µM cisplatin and/or olaparib for 24 hrs. After 24 hrs drug was removed (DR0) and fresh drug free media was added. Cells were cultured further and γH2A.X foci were observed very 24 hr till 10 days post drug removal (DR0 to DR10). Cells with >20 γH2A.X foci to 0 foci were counted in blind fashion and at least 200 cells per group in several different 60× objective fields were acquired. Quantitative plot displaying distribution of γH2A.X foci in three treatment groups in both the cell lines. [Time point DR3, frequency of cells with more than 20 foci per cell in SiHa; cisplatin vs. cisplatin + olaparib *p = 0.0467, at DR4; cisplatin vs. cisplatin + olaparib *p = 0.0268, at DR5; cisplatin vs. cisplatin + olaparib **p = 0.0060 and frequency of cells with more than 20 foci per cell in ME180 at DR3; cisplatin vs. cisplatin + olaparib *p = 0.0390, at DR4; cisplatin vs. cisplatin + olaparib *p = 0.041, at DR5; cisplatin vs. cisplatin + olaparib **p = 0.0024]. (B) Both the cell lines SiHa and ME180 were treated as indicated and cell were stained with FITC tagged anti γH2A.X & co-stained with PI and analysis was done using FACS for DNA damage in each cell cycle phases. Graph showing the percentage of cells with γH2A.X foci in SiHa and ME180 cell lines. PARP1 inhibition in cisplatin treated cells shows significant accumulation of DNA damage in late S and G2/M phase compared to G1. (C) Graph showing frequency of γH2A.X foci resolution in PARP1 silenced and control counterpart after cisplatin treatment. PARP1 silenced cells displayed significant delay in γH2A.X foci resolution after drug removal. (D) Similarly, PARP inhibition along with cisplatin treatment for 48 hrs shows significant & prolonged G2/M and late S phase arrest in both the cell lines after drug removal as in previous experiments.CC BY · PubMed Central
Figure 8 PARP1 inhibition interferes with recruitment of BER effector XRCC1 and NHEJ mediators XRCC4 & KU70/80 at DNA damage site. (A) Representative image of co-immunofluorescence of XRCC1 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (B) Bar graph displaying number of XRCC1 foci and relative co-localization of XRCC1 foci and γH2A.X foci in indicated treatment group. (C) Representative image of co-immunofluorescence of PARP1 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (D) Representative image of co-immunofluorescence of KU80 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (E) Bar graph displaying relative co-localization of KU80 foci and γH2A.X foci in indicated treatment group. (F) Representative image of co-immunofluorescence of XRCC4 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (G) Bar graph displaying relative co-localization of XRCC4 foci and γH2A.X foci in indicated treatment group.
Figure 8 PARP1 inhibition interferes with recruitment of BER effector XRCC1 and NHEJ mediators XRCC4 & KU70/80 at DNA damage site. (A) Representative image of co-immunofluorescence of XRCC1 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (B) Bar graph displaying number of XRCC1 foci and relative co-localization of XRCC1 foci and γH2A.X foci in indicated treatment group. (C) Representative image of co-immunofluorescence of PARP1 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (D) Representative image of co-immunofluorescence of KU80 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (E) Bar graph displaying relative co-localization of KU80 foci and γH2A.X foci in indicated treatment group. (F) Representative image of co-immunofluorescence of XRCC4 and γH2A.X in CC cell line treated with cisplatin and/or olaparib and siRNA as indicated. (G) Bar graph displaying relative co-localization of XRCC4 foci and γH2A.X foci in indicated treatment group.CC BY · PubMed Central
Figure 9 PARP1 inhibition or silencing enhances cisplatin induced apoptosis in cervical cancer cells. (A) Bar graph showing quantification of apoptotic cells in cisplatin and/or olaparib treated cells in both the cell lines. (B) Bar graph showing quantification of apoptotic cells in PARP1 silenced CC cells treated with cisplatin.
Figure 9 PARP1 inhibition or silencing enhances cisplatin induced apoptosis in cervical cancer cells. (A) Bar graph showing quantification of apoptotic cells in cisplatin and/or olaparib treated cells in both the cell lines. (B) Bar graph showing quantification of apoptotic cells in PARP1 silenced CC cells treated with cisplatin.CC BY · PubMed Central
Figure 10 PARP inhibitor suppresses metastatic events in CC. (A) Overnight serum starved SiHa and ME180 cell lines were seeded in transwell insert (8 µm pore size) with or without olaparib for 16 hrs. Representative images show migrated cells stained with crystal violet. (B) Bar graph showing quantitative cell migration in untreated and olaparib treated CC cell lines. (C) Overnight serum starved SiHa and ME180 cell lines were seeded in transwell insert (8 µm pore size) coated with matrigel matrix and 10 µM olaparib was added with the cells for 48 hrs. Representative image shows invaded cells stained with crystal violet. (D) Bar graph showing quantitative cell invasion through matrigel matrix in untreated and olaparib treated CC cell lines. (E) SiHa and ME180 cell were cultured in adherent and suspension condition. Olaparib treatment was done for 24 hrs and cells were stained with PI. Bar graph showing the quantitative distribution of dead cells. (F) Olaparib treated adherent and suspension CC cell lines were co-stained with Annexin V and PI. Bar graph displaying quantitative distribution of apoptotic cells.
Figure 10 PARP inhibitor suppresses metastatic events in CC. (A) Overnight serum starved SiHa and ME180 cell lines were seeded in transwell insert (8 µm pore size) with or without olaparib for 16 hrs. Representative images show migrated cells stained with crystal violet. (B) Bar graph showing quantitative cell migration in untreated and olaparib treated CC cell lines. (C) Overnight serum starved SiHa and ME180 cell lines were seeded in transwell insert (8 µm pore size) coated with matrigel matrix and 10 µM olaparib was added with the cells for 48 hrs. Representative image shows invaded cells stained with crystal violet. (D) Bar graph showing quantitative cell invasion through matrigel matrix in untreated and olaparib treated CC cell lines. (E) SiHa and ME180 cell were cultured in adherent and suspension condition. Olaparib treatment was done for 24 hrs and cells were stained with PI. Bar graph showing the quantitative distribution of dead cells. (F) Olaparib treated adherent and suspension CC cell lines were co-stained with Annexin V and PI. Bar graph displaying quantitative distribution of apoptotic cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

See all 86

Metadata

Authors
Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G.
Affiliations
  • Banaras Hindu University (IN)
  • Institute of Medical Sciences (IN)
Corresponding author
Narayan, Gopeshwar
Venue
Scientific Reports
Published
2017-10-09
Volume
7
Issue
1
Pages
12876-12876
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2762572114
Cited by
84
References
64
Citations by year
2026: 5 · 2025: 9 · 2024: 11 · 2023: 8 · 2022: 14 · 2021: 9 · 2020: 14 · 2019: 10 · 2018: 3 · 2017: 1
FWCI
3.38
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords
olaparib, PARP1, cervical cancer, cisplatin, PARP inhibitors, DNA repair, base excision repair, non-homologous end joining, replication fork collapse, DNA double-strand breaks, apoptosis, cell migration and invasion, anoikis, treatment resistance
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Uterine Cervical Neoplasms, Cisplatin, DNA Repair, DNA Replication, Female, Humans, Neoplasm Metastasis, Nuclear Proteins, Phthalazines, Piperazines, Apoptosis, Gene Silencing, Cell Line, Tumor, DNA Breaks, Double-Stranded, Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. https://app.cochat.ai/papers/10.1038/s41598-017-13232-3
The paper
Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G. (2017). Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Scientific Reports. https://doi.org/10.1038/s41598-017-13232-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.